Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial
Related Posts
DiPentino R, Meza BPL, Jackson N, Dosanjh KK, Dudovitz RN, Wong MD. Could School Function Be an Adolescent Health Vital Sign? Associations Between Gradebook Data[...]
Shi KSY, Dorairaj EA, Bhartiya S, Oyama K, Wang W, Thé RY, Moreno KB, Wang M, Towne C, Qozat IM, Banoub RG, Dorairaj SK. Safety[...]
Brownstein AJ, Shaikh F, Xiao GQ, Wilhalme H, Abtin F, Stefanko DP, Liang LL, Hong J, Rahaghi F, Shino M, Samuel Weigt S, Sayah D,[...]